Infant and adult SCA13 mutations differentially affect Purkinje cell excitability, maturation, and viability in vivo

Jui-Yi Hsieh1,2, Brittany N Ulrich1,2, Fadi A Issa1

  • 1Department of Physiology, David Geffen School of Medicine at UCLA, Los Angeles, United States.

Elife
|July 10, 2020
PubMed

Insights

Infant-onset spinocerebellar ataxia 13 (SCA13) mutations rapidly kill developing neurons by increasing excitability. Adult-onset SCA13 mutations do not affect neuron survival, suggesting distinct disease mechanisms.

Area of Science:

  • Neuroscience
  • Genetics
  • Developmental Biology

Background:

  • Mutations in KCNC3, encoding the Kv3.3 K+ channel, cause spinocerebellar ataxia 13 (SCA13).
  • SCA13 presents with distinct infant or adult onset forms.
  • Purkinje cells are crucial for motor coordination and are affected in SCA13.

Purpose of the Study:

  • To investigate how infant- and adult-onset KCNC3 mutations differentially impact Purkinje cell excitability and survival during cerebellar development.
  • To test the hypothesis that distinct excitability changes underlie different SCA13 onset ages.

Main Methods:

  • Utilized zebrafish as a model organism to study cerebellar development in vivo.
  • Examined the effects of infant- and adult-onset KCNC3 mutations on Purkinje cell excitability, process extension, dendritic branching, synaptogenesis, and viability.
  • Manipulated excitability to assess its role in Purkinje cell survival.

Main Results:

  • An infant-onset mutation transiently increased Purkinje cell excitability, impaired development, and caused rapid cell death.
  • Reducing excitability in early development improved Purkinje cell survival.
  • An adult-onset mutation did not affect basal excitability or cause Purkinje cell degeneration during development.

Conclusions:

  • Differential alterations in Purkinje cell excitability contribute to the distinct clinical presentations and timing of cerebellar degeneration in infant- versus adult-onset SCA13.
  • Targeting excitability may offer therapeutic strategies for SCA13.